Cerebral venous sinus thrombosis: prevention of recurrent thromboembolism. by Nuenen, B.F.L. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/47487
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
B.F.L. van Nuenen, M. Munneke and B.R. Bloem
Cerebral Venous Sinus Thrombosis: Prevention of Recurrent Thromboembolism
Print ISSN: 0039-2499. Online ISSN: 1524-4628 
Copyright © 2005 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Stroke 
doi: 10.1161/01.STR.0000176582.17934.82
2005;36:1822-1823Stroke. 
 http://stroke.ahajournals.org/content/36/9/1822
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://stroke.ahajournals.org//subscriptions/
is online at: Stroke  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer process is available in the
Request Permissions in the middle column of the Web page under Services. Further information about this
Once the online version of the published article for which permission is being requested is located, click 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.Strokein
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at Radboud Universiteit Nijmegen on July 12, 2012http://stroke.ahajournals.org/Downloaded from 
Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. They should not exceed 750 words (including references)
and may be subject to editing or abridgment. Please submit letters in duplicate, typed double-spaced. Include a fax number for the corresponding author and
a completed copyright transfer agreement form (published in every issue).
Protein Z Levels, Protein Z G79A
Polymorphism, and Prothrombotic Conditions
To the Editor:
We read with great interest the article on protein Z gene
polymorphisms, protein Z concentrations, and ischemic stroke
published by Staton et al.1 The authors examine protein Z
concentrations and 2 common polymorphisms of the protein Z
gene in patients with a first-ever ischemic stroke and conclude
that high levels of protein Z are prothrombotic and that the 79AA
genotype of the G79A polymorphism is protective for the
ischemic stroke.
The conclusions drawn by Staton et al seem questionable
because of several flaws.
First, the hypothesis that high levels of protein Z are prothrom-
botic is, to date, not supported by the pathophysiology, because
the role of protein Z has been demonstrated to be the inhibition
of activated factor X through the formation of a complex with
protein Z–dependent protease inhibitor. Consequently, low lev-
els of protein Z are expected to be prothrombotic. In line with
this theory, the majority of the studies in this field have reported
low levels of protein Z in association with prothrombotic
conditions. Actually, only 2 studies have reported that high levels
of protein Z are prothrombotic, but methodological biases are
detectable. In the former, the investigators modified the commer-
cial assay and used a normal plasma pool.2 In the latter, the
control group included subjects with a previous vascular event.3
Second, Staton et al reported lower levels of protein Z plasma
in controls with respect to all the other case-control studies
present in the literature, including reports with a greater number
of subjects analyzed. This might be attributable to the presence of
subjects with a previous vascular event (not better clarified)
included in the control group. Actually, patients with vascular
diseases have been reported to have low levels of protein Z.4
Third, the significant result of the 79A allele as a protective
factor for the ischemic stroke has been performed by pooling
data from a previous study. Actually, a pooled analysis in
case-control studies, especially for the evaluation of genetic
polymorphisms, is rather a questionable approach. To perform
this kind of analysis, the 2 populations should be homogenous
and similar for the main parameters investigated. Conversely, the
Staton et al do not explain how they tested the homogeneity of
the 2 populations, particularly with regard to genetic background
and prevalence of the traditional cardiovascular risk factors. Too
many differences (first of all, age) between such distant and
different populations are detectable to correctly perform this
analysis.
In fact, the analysis performed in their single population
demonstrated no significant relationship between both the poly-
morphisms and the ischemic stroke; the only significant result
derives from pooling data from the study by Lichy et al5 and is
also determined by an overall low number of homozygotes for
the AA genotype (n32), thereby not reaching a sufficient
statistical power.
In consideration of all these limitations, we do not believe that
the conclusions stated by Staton et al, ie, high levels of protein Z
prothrombotic and 79A allele protective for the ischemic stroke,
can be drawn from this study. Because low protein Z plasma
levels have been reported in several studies to be associated with
different prothrombotic conditions, it can be hypothesized that
protein Z is either simply a marker of the disease or influenced
by the acute phase, but it is at least questionable, to date, to
postulate that high levels of protein Z are associated with
prothrombotic conditions and that 79AA genotype is protective
for the ischemic stroke.
Francesco Sofi, MD
Francesca Cesari, BS
Gian Franco Gensini, MD
Rosanna Abbate, MD
Sandra Fedi, BS
Department of Medical and Surgical Critical Care
Thrombosis Centre, University of Florence and
Department of Heart and Vessels
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
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Response:
Dr Sofi and colleagues question our conclusion that the
consistency of the association between protein Z genotype,
elevated blood concentrations of protein Z, and ischemic stroke
strengthens the evidence that increased blood concentrations of
protein Z concentrations are causally associated with the risk of
ischemic stroke.1
First, they propose that our conclusion is not supported by
pathophysiology, citing methodological bias as an explanation
for previous reports of elevated blood concentrations protein Z in
stroke patients. However, they provide no explanation of how the
use of a normal plasma pool may have biased the results of the
study by Kobelt et al.2 In the study by McQuillan et al,3 removal
of control subjects with a previous vascular event from the
analysis does not change the results or conclusions.
Second, as indicated by Sofi et al, blood concentrations of
protein Z in our study were lower than previously reported in
several other studies, including their own.4 The reason for this is
unclear, although could potentially be related to prolonged
storage of blood samples before measuring protein Z levels.3
However, irrespective of the cause, our within-study compari-
sons of protein Z concentrations in stroke cases and controls
remain valid because the duration of storage of samples for cases
and controls was similar and all laboratory samples were col-
lected, processed, stored, and analyzed in the same manner.
Third, Sofi and colleagues question our approach of pooling
results from case control studies to clarify the association
between protein Z polymorphisms and ischemic stroke. How-
ever, this is a well-established technique that is commonly used
for aggregating previous research when individual studies have
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insufficient power to detect an association.5 Taken together with
the data by Lichy et al,6 we believe that our study results are
consistent with the conclusion that elevated blood concentrations
of protein Z are prothrombotic.
John W. Eikelboom
Department of Medicine
McMaster University
Hamilton, Canada
Janelle Staton
Department of Hematology
Royal Perth Hospital
Perth, Australia
Graeme J. Hankey
School of Medicine and Pharmacology
University of Western Australia
Perth, Australia
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Cerebral Venous Sinus Thrombosis:
Prevention of Recurrent Thromboembolism
To the Editor:
Patients who have recovered from cerebral venous sinus
thrombosis (CVST) are at risk for sustaining a recurrence of
CVST or other thrombotic events (Table). For example, in the
recent International Study on Cerebral Vein and Dural Sinus
Thrombosis (ISCVT) that was performed in 624 patients with
cerebral vein or dural sinus thrombosis, the cumulative risk for
recurrent CVST or other thrombotic events after CVST was
6.5%.1 Recurrent thrombosis is potentially fatal. Therefore, an
important clinical question is whether recurrence of CVST or
other thrombotic events can be prevented in this group.
Currently, the standard care for patients with a first episode of
CVST is anticoagulation therapy, which is usually prescribed for 3
to 6 months in the absence of an identifiable cause.2 However,
controlled data about the benefit and optimal duration of oral
anticoagulation in patients with CVST are missing.3 More pro-
longed treatment may be required, because the cumulative risk for
recurrent CVST or other thrombotic events after 3 to 6 months of
oral anticoagulation therapy ranges between 5.5 and 26% (calcu-
lated over a mean follow-up period of 18 to 77.8 months).2,4,5 At the
time of these recurrences, which mostly occurred within 1 year,
none of the patients received anticoagulation therapy. In the recent
ISCVT study, 58.8% of the patients with a recurrence of thrombotic
event were not undergoing anticoagulation therapy.1 The signifi-
cance of these observations is underscored by the fact that recur-
rence of cerebral venous thrombosis after stopping anticoagulation
therapy can occasionally run a fatal course.6
The need for more chronic treatment is further supported by
recent observations on the effects of prolonged anticoagulant
therapy in patients with idiopathic venous thromboembolism
(either pulmonary or deep venous thrombosis).7 This study
evaluated the efficacy of long-term, low-intensity warfarin ther-
apy (international normalized ratio, 1.5 to 2.0) in preventing
recurrent thrombotic events among patients with idiopathic
venous thromboembolism who had completed at least 3 months
of therapy with conventional-dose warfarin. Compared with
placebo, long-term and low-intensity warfarin afforded a risk
reduction for recurrent thromboembolism of 64% over a mean
follow-up period of 2.1 years.
The practical implication was that clinical practice should presum-
ably consist of this prolonged, low-intensity anticoagulant regime, at
least for patients with a prior event of pulmonary or deep venous
thrombosis.7 In this particular study, patients with CVST were not
specifically studied. However, it seems justified to extrapolate the
findings on pulmonary embolism or deep venous thrombosis to CVST,
because the underlying risk factors associated with these conditions are
identical.8 Thus, applying this potential risk reduction of 64% to the
ISCVT study, long-term anticoagulation therapy could have prevented
recurrent thromboembolism in 15 of the 24 patients where recurrence
occurred in the absence of anticoagulants. In other words, prolonged
anticoagulation in the ISCVT study could have resulted in a cumulative
risk for recurrent CVST and other thrombotic events of 4.1%, instead of
6.5%.
We, therefore, suggest that, to reduce recurrence of thrombotic
events after CVST, it may be prudent to treat these patients with
long-term anticoagulation therapy. Future research should deter-
mine the optimal duration and intensity of oral anticoagulation
therapy that is necessary to optimally reduce the risk for
recurrence of thrombotic events.
B.F.L. van Nuenen, MD
M. Munneke, PhD
B.R. Bloem, MD
Department of Neurology
Radboud University Nijmegen Medical Centre
The Netherlands
Cumulative Risk for Recurrence of Thrombotic Events After a First Episode of CVST (Overview of
Published Studies)
Study
No. of
Patients
Mean Follow-Up
(Months)
Duration of OAC
Treatment (Months)
Cumulative Recurrence of
Thromboembolism (%)
ISCVT study1 624 18 Mean of 7.7 6.5
Preter et al4 77 78 3 to 4 26.0
Breteau et al2 55 36 6 (56.4% of patients) 5.5*
6–36 (12.7% of patients)
36 (30.9% of patients)
VENOPORT study7 Not reported 22 Not reported 5.0
*Two patients with protein S deficiency. OAC indicates oral anticoagulation.
1822 Letters to the Editor
 at Radboud Universiteit Nijmegen on July 12, 2012http://stroke.ahajournals.org/Downloaded from 
1. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F;
ISCVT Investigators. Prognosis of cerebral vein and dural sinus throm-
bosis: results of the International Study on Cerebral Vein and Dural Sinus
Thrombosis (ISCVT). Stroke. 2004;35:664–670.
2. Breteau G, Mounier-Vehier F, Godefroy O, Gauvrit JY, Mackowiak-
Cordoliani MA, Girot M, Bertheloot D, Henon H, Lucas C, Leclerc X,
Fourrier F, Pruvo JP, Leys D. Cerebral venous thrombosis 3-year clinical
outcome in 55 consecutive patients. J Neurol. 2003;250:29–35.
3. Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus
thrombosis. J Neurol. 2004;251:11–23.
4. Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral
venous thrombosis. Follow-up of 77 patients. Stroke. 1996;27:243–246.
5. Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J. Long-term
prognosis of cerebral vein and dural sinus thrombosis. Results of the
VENOPORT study. Cerebrovasc Dis. 2002;13:272–278.
6. van den Berg JS, Boerman RH, vd Stolpe A, Kremer HP. Cerebral venous
thrombosis: recurrence with fatal course. J Neurol. 1999;246:144–146.
7. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher
SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T,
Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ;
PREVENT Investigators. Long-term, low-intensity warfarin therapy for
the prevention of recurrent venous thromboembolism. N Engl J Med.
2003;348:1425–1434.
8. de Bruijn. Cerebral Versus Sinus Thrombosis. Clinical and Epidemio-
logical Studies. Amsterdam: Thesis Publishers; 1998.
Inosine, Calcium Channels, and Neuroprotection
Against Ischemic Brain Injury
To the Editor:
We read with great interest the article by Shen et al,1 dealing
with neuroprotective effects of inosine against ischemic brain
injury. The results of their study demonstrated that intracerebro-
ventricular administration of inosine before middle cerebral
artery occlusion in rats resulted in a higher level of locomotor
activity and less cerebral infarction. In addition, they indicated
that coadministration of selective A3 receptor antagonist
MRS1191 significantly attenuated inosine-mediated protection.
In the electrophysiological study, it was shown that inosine
antagonized glutamate-induced excitation in cerebral cortical
neurons. The authors proposed that inosine may inhibit glutamate
postsynaptic responses and reduce cerebral infarction via the
activation of A3 receptors.
Several studies have shown the mechanisms for glutamate-
induced excitation of neural cells. In a study we presented earlier,
changes in acetylcholine (ACh) release evoked by glutamate was
investigated in rat central nervous system.2,3 In an in vitro study,
we showed that glutamate increased the release of ACh from rat
striatum, which was inhibited by the N-methyl-D-aspartate type
of glutamate receptor antagonist MK-801.3 Furthermore, it was
demonstrated that the calcium-channel blocker verapamil signif-
icantly reduced glutamate-evoked ACh release and that the
inhibitory effect was more pronounced in the presence of
magnesium.2 It might be possible that the calcium-channel
blocker could inhibit the N-methyl-D-aspartate receptor–depen-
dent calcium current in neural cells. It was also shown that the
calcium-channel blocker nilvadipine blocked glutamate-evoked
intracellular calcium increase with a concomitant reduction in
glutamate-induced apoptosis in purified retinal ganglion cells,4
suggesting that the calcium-channel blocker might inhibit
glutamate-induced apoptotic cell death by blocking calcium
influx. Therefore, we would like to know whether inosine and
calcium-channel blockers might have a synergistic effect in
neural protection in the present study by Shen et al. Although the
authors demonstrated that inosine did not alter basal glutamate
release, nor did it reduce ischemia-evoked glutamate overflow in
the central nervous system, it can be speculated that inosine
might interfere with glutamate receptor–mediated calcium con-
ductance in neural cells and might have therapeutic potential as
a neuroprotective agent against stroke-induced damage.
Kazushi Tsuda, MD, FAHA
Division of Cardiology
Department of Medicine
Wakayama Medical University
Wakayama, Japan
1. Shen H, Chen GJ, Harvey BK, Bickford PC, Wang Y. Inosine reduces
ischemic brain injury in rats. Stroke. 2005;36:654–659.
2. Tsuda K, Tsuda S, Goldstein M, Masuyama Y. Inhibitory effects of
verapamil on [3H]-acetylcholine release in the central nervous system of
Sprague-Dawley rats. Clin Exp Pharmacol Physiol. 1994;21:527–531.
3. Tsuda K, Tsuda S, Goldstein M, Nishio I, Masuyama Y. Glutamatergic
regulation of [3H]-acetylcholine release in striatal slices of normotensive
and spontaneously hypertensive rats. Neurochem Int. 1996;29:231–237.
4. Otori Y, Kusaka S, Kawasaki A, Morimura H, Miki A, Tano Y. Pro-
tective effect of nilvadipine against glutamate neurotoxicity in purified
retinal ganglion cells. Brain Res. 2003;961:213–219.
Response:
We thank Dr Tsuda for expressing interest in our article.1 As
indicated by Dr Tsuda, increasing evidence has suggested that
calcium channels are involved in glutamate-mediated neurode-
generation. In our study, we reported that inosine suppresses
glutamate-evoked neuronal excitation in cerebral cortex. It is
possible that inosine may have indirect actions on calcium
channels through the inhibition of glutamate response during
cerebral ischemia. Currently, there are no reports suggesting that
calcium-channel blockers have synergistic effects on inosine-
mediated response in the central nervous system. Our prelimi-
nary studies showed that an N-type calcium channel blocker had
a trend toward increasing inosine-mediated protection against
ischemic brain injury in adult Sprague-Dawley rats. Animals
were injected intracerebroventricularly, before middle cerebral
artery occlusion (MCAo), with -conotoxin GVIA (0.1 g/10
L, n6) or -conotoxin GVIAinosine (25 nmol, n7).
Compared with our previous data,1 -conotoxin GVIA alone did
not significantly reduce the size of infarction. Coadministration
of -conotoxin GVIA and inosine significantly reduced vol-
ume of infarction compared with the stroke animals pretreated
with vehicle (52.128.9 mm3 versus 187.19.0 mm3;
P0.05; 1-way ANOVA). Although the mean of infarction
volume is further reduced by -conotoxin GVIA in the
animals pretreated with inosine, the difference in protection
between -conotoxin GVIAinosine (52.128.9 mm3) and
inosine alone (118.518.4 mm3) is not statistically signifi-
cant. We observed that the majority of animals that received
-conotoxin GVIA with or without inosine developed sei-
zures after MCAo. Other studies have shown nifedipine or
felodipine suppressed hypoxia-evoked inosine release in rat
cerebral cortex.2 The combined effects of inosine and calcium
channel blockers in cerebral ischemia are complicated by such
observations. Further studies are needed to definitively ad-
dress the interaction of inosine and calcium channels.
Hui Shen, MD
Guann-Juh Chen, MD
Brandon Harvey, PhD
Yun Wang, MD, PhD
Neural Protection and Regeneration Section
National Institute on Drug Abuse
Baltimore, Md
1. Shen H, Chen G-J, Harvey BK, Bickford PL, Wang Y. Inosine reduces
ischemic brain injury in rats. Stroke. 2005;36:654–659.
2. Phillis JW, O’Regan MH, Walter GA. Effects of nifedipine and felodipine
on adenosine and inosine release from the hypoxemic rat cerebral cortex.
J Cereb Blood Flow Metab. 1988;8:179–185.
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Comment on the Phosphodiesterase 4D
Replication Study by Bevan et al
To the Editor:
We observe with interest the results of the study by Bevan et
al,1 where they attempted to replicate our findings associating the
PDE4D gene with stroke. We appreciate the effort by the authors
and their presentation of their data in some detail. The latter
allowed us to compare their results with ours, including some
unpublished results. In our original publication,2 the main find-
ings are summarized in Figure 4, where haplotypes are grouped
into 3 categories: the at-risk haplotypes, the “wild-type,” and the
protective haplotype. Although the definition of the at-risk
haplotypes involved multiple markers, the protective haplotype,
in our data, is characterized by one single-nucleotide poly-
morphism, specifically allele A of SNP45. This makes it partic-
ularly suitable for a replication in a different population. In Table
I of Bevan et al, allele A has frequency of 15.4% in 621 stroke
patients and 18.7% in 848 controls. We calculated that this
corresponds to 191 copies of allele A and 1051 Gs in stroke
patients, and 317 As and 1379 Gs in controls. Applying Fisher
exact test gives a 2-sided probability value of 0.02 and a 1-sided
probability value of 0.01. For the same allele counts, estimated
risk of A relative to G is 0.79, or equivalently risk of G relative
to A is 1.26. This agrees well with our estimated relative risk of
1.33 for allele G for all stroke patients (in Table 1 of Gretarsdottir
et al2). Hence, even though Bevan et al did not consider this
result as significant, which could be attributable to the use of
somewhat different statistical tests and adjustment for multiple
comparisons, we are nonetheless encouraged by these results,
especially because we have obtained similar results for SNP45 in
a replication study of ours (Gretarsdottir et al, unpublished data,
2005). In summary, we appreciate the difficulties of getting
definitive results for a replication study when the effect of the
variant may only be modest and proper care has to be taken to
adjust for multiple testing of variants and phenotypes. And we
agree with the authors that further investigation is needed to
develop a better understanding of the role of PDE4D in stroke.
Solveig Gretarsdottir, PhD
Jeffrey Gulcher, MD, PhD
Gudmar Thorleifsson, PhD
Augustine Kong, PhD
Kari Stefansson, MD, DrMed
DeCODE Genetics
Reykjavik, Iceland
1. Bevan S, Porteous L, Sitzer M, Markus HS. Phosphodiesterase 4D gene,
ischemic stroke, and asymptomatic carotid atherosclerosis. Stroke. 2005;
36:949–953.
2. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir
S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir S, Einarsson OB,
Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H,
Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias
J, Goss S, Sveinbjo¨rnsdottir S, Valdimarsson E, Jakobsson F, Agnarsson
U, Gudnason V, Kong A, Thorgeirsson G, Fingerle J, Gurney M, Frigge
ML, Kong A, Stefansson K, Gulcher JR. The gene encoding phosphodi-
esterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35:131–138.
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